Actively Recruiting
Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis
Led by Centre Hospitalier Universitaire de Besancon · Updated on 2024-02-01
43
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Echinococcosis is a serious parasitic disease caused by tapeworm larvae, leading to alveolar or cystic echinococcosis. Treatment often involves surgery or benzimidazole drugs like albendazole, which slows parasite growth but doesn't kill it, requiring lifelong use and regular monitoring. Diagnosis uses imaging and blood tests, but sensitivity varies, especially in patients with weakened immune systems. Researchers are evaluating a new multiplex quantitative PCR (QPCR-Echino) test to detect DNA from the parasites in blood and tissues, aiming to improve diagnosis and monitoring, particularly in immunocompromised patients who face delays in diagnosis. The study involves collecting blood samples to perform the new QPCR-Echino test at the start and after one year. This test targets DNA from Echinococcus multilocularis and Echinococcus granulosus species found in Europe. The goal is to assess how well this new technique performs compared to current methods for diagnosing echinococcosis. Participants will provide blood samples upon joining the trial and again after one year. Researchers will analyze these samples using the QPCR-Echino method to evaluate diagnostic accuracy and effectiveness over time. The study will measure performance indicators of this diagnostic technique within one year, helping to improve detection and management of echinococcosis. The total participation time includes initial and one-year follow-up blood testing.
CONDITIONS
Brief Title
Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged >18 years with a diagnosis of echinococcosis (Alveolar or Cystic) according to reference criteria
- Signed informed consent confirming understanding and agreement to participate
- Affiliation to or beneficiary of a French social security scheme
You will not qualify if you...
- Legal incapacity or limited legal capacity
- Unlikely to cooperate or expected low cooperation
- No health insurance
- Pregnant women
- Currently excluded from another study or listed in the national volunteer file
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 year
Participants provide blood samples for evaluation using the new multiplex quantitative PCR technique at inclusion and one year later.
2 visits (in-person)
Trial Site Locations
Total: 1 location
1
MILLON
Besançon, France, 25000
Actively Recruiting
Research Team
L
Laurence MILLON, PharmD, PhD
J
Jenny KNAPP, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here